Trials / Active Not Recruiting
Active Not RecruitingNCT06722729
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
A Late Phase II Clinical Trial of KDT-3594 in Patients With Advanced Parkinson's Disease With Levodopa
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.
Detailed description
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered once daily in patients with advanced PD with levodopa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KDT-3594 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2024-12-16
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2024-12-09
- Last updated
- 2026-03-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06722729. Inclusion in this directory is not an endorsement.